INmune Bio (NASDAQ:INMB) Receives “Sell (E+)” Rating from Weiss Ratings

INmune Bio (NASDAQ:INMB)‘s stock had its “sell (e+)” rating restated by Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

Other equities analysts have also issued research reports about the stock. Wall Street Zen lowered shares of INmune Bio from a “hold” rating to a “sell” rating in a report on Saturday, August 2nd. Scotiabank reiterated a “sector underperform” rating on shares of INmune Bio in a report on Tuesday, July 1st. Maxim Group decreased their price target on shares of INmune Bio from $30.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, July 2nd. Raymond James Financial lowered shares of INmune Bio from a “moderate buy” rating to a “hold” rating in a report on Monday, June 30th. Finally, BTIG Research reiterated a “neutral” rating on shares of INmune Bio in a report on Tuesday, July 1st. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, two have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, INmune Bio has a consensus rating of “Hold” and a consensus price target of $18.50.

INmune Bio Stock Performance

Shares of INMB opened at $2.01 on Wednesday. The stock has a fifty day moving average of $2.19 and a two-hundred day moving average of $4.85. The company has a market capitalization of $53.43 million, a PE ratio of -0.81 and a beta of 1.04. INmune Bio has a fifty-two week low of $1.71 and a fifty-two week high of $11.64.

INmune Bio (NASDAQ:INMB) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.03. As a group, equities research analysts forecast that INmune Bio will post -2.24 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Rhumbline Advisers lifted its position in shares of INmune Bio by 14.4% during the first quarter. Rhumbline Advisers now owns 19,153 shares of the company’s stock worth $150,000 after purchasing an additional 2,409 shares in the last quarter. Cambridge Investment Research Advisors Inc. acquired a new position in shares of INmune Bio during the first quarter worth $180,000. Bank of America Corp DE lifted its position in shares of INmune Bio by 15.2% during the fourth quarter. Bank of America Corp DE now owns 30,449 shares of the company’s stock worth $142,000 after purchasing an additional 4,015 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of INmune Bio by 19.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 41,320 shares of the company’s stock worth $323,000 after purchasing an additional 6,654 shares in the last quarter. Finally, Pekin Hardy Strauss Inc. lifted its position in shares of INmune Bio by 13.1% during the first quarter. Pekin Hardy Strauss Inc. now owns 94,300 shares of the company’s stock worth $736,000 after purchasing an additional 10,950 shares in the last quarter. 12.72% of the stock is owned by institutional investors and hedge funds.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.